A strong week with spreads 4.5bps tighter led by Eurofins and Bayer. These moves reflect beta rather than anything company specific. Viatris, however, did not benefit from the risk-on move as it is placing equity ahead of credit to placate shareholders.
• US Pharma Policy: Politico carried a piece which stated that Trump would use executive orders to enforce “most favoured nation” status for US Pharma imports to cut the price paid by Medicare for leading drugs. At the FDA, Vinay Prasad was appointed director of the Center for Biologics Evaluation and Research. As a leading opponent of Biden’s vaccination policy this could be negative for AZN, Sanofi, GSK and Pfizer.
• Sanofi was upgraded to Aa3 by Moody’s
• Earnings: Zimmer Biomet (Small Negative) tariffs to have larger impact in 2026, equity fell 12% but recovered half ; Philips (Small Negative) cut margin guidance and Respironics payouts consumed free cash; Fresenius Medical (Small Positive); Coloplast (Neutral) reduced guidance but is also cutting leverage; Novo Nordisk (Neutral) reduced guidance but from very high levels; Fresenius SE (Neutral); Takeda (Small Positive) reduced leverage, has limited tariff exposure and is replacing Vyanse with new products; Viatris (Negative) prioritising shareholders over creditors; Lonza (Small Positive) confirms +20% sales growth and 30% margin targets, limited tariff exposure.

Find more articles and bullets on these widgets:
TD Securities recommended longs in 30-Year gilts at 5.62%, targeting a move to 5.10%, with a stop set at 5.90%.
Key fiscal/economic measures announced by the incoming CDU/CSU/SPD coalition below. These broadly match the announcements seen in local media earlier today. Note that in Germany, an announcement of measures as part of a coalition agreement does not necessarily mean these will be implemented. Overall, the government seems to be planning to make use of the newly increased fiscal headroom:
Full coalition agreement pdf document available online, link here.